# Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer

> **NCT06624878** · NA · COMPLETED · sponsor: **Zhejiang Cancer Hospital** · enrollment: 568 (actual)

## Conditions studied

- Ovarian Cancer
- Cytoreductive Surgery
- Depressive Symptom

## Interventions

- **DRUG:** esketamine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06624878
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-08
- **Primary completion:** 2026-01-14
- **Final completion:** 2026-02-14
- **Target enrollment:** 568 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06624878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06624878, "Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06624878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*